Differential effects of strength training and testosterone treatment on soluble CD36 in aging men: Possible relation to changes in body composition

References

• Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012;34:145–56.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011;96:2643–51.
   PubMed Web of Science ®Google Scholar
• Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, Frystyk J, Brixen K, Andersen M. Testosterone therapy decreased subcutaneous fat and adiponectin in ageing men. Eur J Endocrinol 2012;166: 469–76.
   PubMed Web of Science ®Google Scholar
• Frederiksen L, Glintborg D, Hojlund K, Hougaard DM, Brixen K, Rasmussen LM, Andersen M. Osteoprotegerin levels decrease during testosterone therapy in aging men and are associated with changed distribution of regional fat. Horm Metab Res 2013;45:308–13.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Christensen LL, Kvorning T, Larsen R, Brixen K, Hougaard DM, Richelsen B, Bruun JM, Andersen M. Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men. Mediators Inflamm 2013;2013:539156.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–22.
   PubMed Web of Science ®Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560–75.
   PubMed Web of Science ®Google Scholar
• Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805.
   PubMed Web of Science ®Google Scholar
• Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29–39.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112: 1796–808.
   PubMed Web of Science ®Google Scholar
• Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108:785–91.
   PubMed Web of Science ®Google Scholar
• Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;113:764–73.
   PubMed Web of Science ®Google Scholar
• Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 2003;167:129–34.
   PubMed Web of Science ®Google Scholar
• Koonen DP, Jensen MK, Handberg A. Soluble CD36 – a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem 2011;117:57–63.
   PubMedGoogle Scholar
• Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049–56.
   PubMed Web of Science ®Google Scholar
• Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006;114:1169–76.
   PubMed Web of Science ®Google Scholar
• Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, Larsen R, Andersen M. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 2007;92:2696–705.
   PubMed Web of Science ®Google Scholar
• Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber CC, Kaufman JM, Abellan van KG, Boonen S, Adachi J, Mitlak B, Tsouderos Y, Rolland Y, Reginster JY. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int 2012;23:1839–48.
   PubMed Web of Science ®Google Scholar
• Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006;290:E961–967.
   PubMed Web of Science ®Google Scholar
• Kvorning T, Christensen LL, Madsen K, Nielsen JL, Gejl KD, Brixen K, Andersen M. Mechanical muscle function and lean body mass during supervised strength training and testosterone therapy in aging men with low normal testosterone levels – a placebo-controlled, randomized, double-blind study. J Am Geriatr Soc 2013;61:957–62.
   PubMed Web of Science ®Google Scholar
• Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjonneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quiros JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–20.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
   PubMed Web of Science ®Google Scholar
• Mosbech TH, Pilgaard K.A. VALR. Automatic segmentation of abdominal adipose tissue in MRI. Lect Notes Computer Sci 2011;6688:501–11.
   Google Scholar
• Altman DG. Comparing groups – continuous data. Practical statistics for medical research. 1st edn. London: Chapman and Hall; 1991. pp. 199–202.
   Google Scholar
• Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab 2010;95:1939–46.
   PubMed Web of Science ®Google Scholar
• Handberg A, Hojlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012;271:294–304.
   PubMed Web of Science ®Google Scholar
• Knosgaard L, Thomsen SB, Stockel M, Vestergaard H, Handberg A. Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals. Nutr Diabetes 2014;4:e114.
   PubMed Web of Science ®Google Scholar
• Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues – the biology of pear shape. Biol Sex Differ 2012;3:13.
   PubMed Web of Science ®Google Scholar
• Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A, Brixen K, Andersen M. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 2009;94:4010–5.
   PubMed Web of Science ®Google Scholar
• Lucotti P, Monti LD, Setola E, Galluccio E, Gatti R, Bosi E, Piatti P. Aerobic and resistance training effects compared to aerobic training alone in obese type 2 diabetic patients on diet treatment. Diabetes Res Clin Pract 2011;94: 395–403.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25:337–53.
   PubMed Web of Science ®Google Scholar
• Nielsen TL, Hagen C, Wraae K, Bathum L, Larsen R, Brixen K, Andersen M. The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20–29-year-old Danish men: Odense Androgen Study. Eur J Endocrinol 2010;162: 795–804.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Rosenthal DI, Rosol MS, Anderson EJ, Hayden DL, Schoenfeld DA, Klibanski A. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Am J Roentgenol 1998;170:423–7.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280–93.
   PubMed Web of Science ®Google Scholar